DiaPep277
Phase 3- Indications
- Type 1 diabetes
Company intelligence / Profile preview
DeveloGen was a German biopharmaceutical company specializing in the discovery and development of novel therapeutics for metabolic and endocrine diseases such as type I/II diabetes and obesity. Its pipeline included small molecules targeting insulin resistance, growth factors promoting beta-cell regeneration/survival, a somatostatin analogue in early clinical trials for acromegaly/carcinoid tumors/diabetic retinopathy, as well as DiaPep277—a synthetic peptide immunomodulator that reached pivotal Phase III trials through partnership with Andromeda/Teva. The company was acquired by Evotec AG in July of 2010.
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DeveloGen AG.